Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions
Dr.
Abstracts Summary at
Mazdutide Oral Presentations
1. Title: Mazdutide versus Semaglutide in Chinese Adults with Type 2 Diabetes and Obesity (DREAMS-3): A Randomized, Open-Label Phase 3b Clinical Trial
Abstract No.: 1226-OR
Time:
Presenter: Professor
2. Title: Efficacy and Safety of Mazdutide 9 mg in Chinese Adults with Obesity: Results from the Phase 3 GLORY-2 Clinical Trial
Abstract No.: 1225-OR
Time:
Presenter: Dr.
3. Title: Safety, Tolerability and Pharmacokinetics of Once-Weekly Mazdutide in Chinese Adolescents with Obesity: A Phase 1b Clinical Trial
Abstract No.: 1133-OR
Time:
Presenter: Professor Chunxiu Gong,
These three studies together cover type 2 diabetes with obesity, adult with obesity and adolescent obesity, and will comprehensively demonstrate the clinical value of mazdutide in weight management, glycemic control and metabolic improvement, further strengthening its differentiated positioning as a next‑generation GCG/GLP‑1 dual receptor agonist in the obesity and metabolic disease areas.
Mazdutide Poster Presentations
4. Title: Mazdutide, a GCGR/GLP-1R Dual Agonist, Alleviates MASH and Liver Fibrosis through Hepatocytes–Hepatic Stellate Cells Cross Talk*
Abstract Number: 2505-P
Date & Time:
Presenter: Dr.
5. Title: Dual GLP-1R/GCGR Activation Reprograms Systemic and Hepatic Metabolism to Ameliorate MAFLD*
Abstract Number: 1686-P
Date & Time:
Presenter: Dr.
*Abstracts 2505-P & 1686-P are from investigator-initiated clinical trials (IIT).
Next-gen Innovative Pipeline Poster Presentations
1. Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI3032, a Novel Oral Nonpeptide GLP-1 Receptor Agonist: Single- and Multiple-Ascending Dose Studies in Chinese Adults
Abstract No.: 1690-P
Time:
Presenter: Dr.
2. Title: IBI3032: An Orally Bioavailable Nonpeptidic GLP-1 Receptor Agonist Advancing Through Phase 1 Clinical Trials
Abstract No.: 1678-P
Time:
Presenter: Dr.
3. Title: IBI3040, a Novel Amylin Analog, Induces Superior Weight Loss in Preclinical Models
Abstract No.: 3077-LB
Time:
Presenter: Dr.
4. Title: IBI3042: A Novel Oral Once-Weekly Small-Molecule GLP-1 Receptor Agonist for Type 2 Diabetes and Obesity
Abstract No.: 2543-P
Time:
Presenter: Dr.
5. Title: IBI3046, an INHBE siRNA, Enables High Quality and Long-Lasting Weight Control in Preclinical Study
Abstract No.: 2662-P
Time:
Presenter: Dr. Xiguang Zhang,
Taken together, IBI3032 and IBI3042, as next‑generation oral daily and weekly GLP‑1 receptor agonists, along with IBI3040 (a novel amylin analog) and IBI3046 (an INHBE-targeting siRNA), form a layered and differentiated innovation portfolio for Innovent in the global obesity and metabolic comorbidity space. These programs are designed to address key global obesity challenges, including improving tolerability, reducing muscle loss, extending dosing intervals, maintaining durable weight loss, and comprehensively managing obesity‑related comorbidities.
About Innovent
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 18 products in the market. It has 5 assets in Phase III or pivotal clinical trials and 14 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and
Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.
Forward-looking statement
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions.
The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.
View original content:SOURCE
